FindTrial
Sign In

Study on the evolution of blood stasis syndrome in coronary heart failure and the intervention mechanism of traditional Chinese medicine based on the combination of disease and syndrome

Study on the evolution of blood stasis syndrome in coronary heart failure and the intervention mechanism of traditional Chinese medicine based on the combination of disease and syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005816
Enrollment
Unknown
Registered
2022-04-05
Start date
2022-04-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Qi deficiency and blood stasis groupe:Traditional western medicine treatment plus Buyang Huanwu Decoction
Yang deficiency and blood stasis combined with water in-drinking stop groupe:Traditional western medicine treatment plus Shenfu Yixin Granules

Sponsors

The First Affiliated Hospital of He'nan University of CM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) 18 years old =age=80 years old; (2)Meet the diagnostic criteria of chronic heart failure and coronary heart disease in western medicine; (3) Comply with the syndrome differentiation standard of chronic heart failure with Qi deficiency and blood stasis or compy with the syndrome differentiation standard of Yang deficiency and blood stasis combined with water in-drinking stop syndrome; (4) NYHA classification of heart function is ?~?; (5) Sign the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: (1)Patients with acute coronary syndrome, acute pulmonary embolism or acute cerebrovascular diseases; (2)Patients complicated with other diseases,such as valvular heart disease, Dilated cardiomyopathy, Hypertensive cardiovascular disease, pulmonary heart disease, and congenital heart disease, etc.; (3) Patients with Hypertention or diabetes and poor controlled after drug therapied; (4)Patients with severe liver and kidney dysfunction or terminal stage of malignant tumor; (5) Patients considered to be at the stage of active tuberculosis or with a wide variety of rheumatic diseases; (6) Patients with hemopathy, toxuria or post solid organ transplant; (7) Mental patients or Suspecting or ensuring with a history of taking drugs; (8)Those who have participated in other clinical trials within the past 1 months; (9)Pregnant or lactating women, or planned pregnancy; (10)Those who have taken Traditional Chinese medicine decoction or Chinese patent medicine in the last one week.

Design outcomes

Primary

MeasureTime frame
NYHA;Chinese medicine symptom complex score;NT-proBNP;Echocardiogram;6MWD;—

Countries

China

Contacts

Public ContactZhu Mingjun

First Affiliated Hospital of Henan University of Traditional Chinese MedicineThe First Affiliated Hospital of He'nan University of CM

zhumingjun317@163.com13903846672

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026